Use of particle vectors in immunomodulation
AssigneesBiovector Therapeutics, S.A., Institut Gustave Roussy
InventorsRoger Kravtzoff, Didier Betbeder, Michel Major, Olivier Balland, Samir El Mir, Frederic Triebel, Anne Casanova
Life of this patent
Estimating the term…
Abstract
The invention pertains to use of a vector of the type comprising a nonliquid hydrophilic core for the preparation of a medication intended for the treatment of cancers and/or viral diseases, the vector being combined in the medication with at least one substance other than an antigen capable of modulating the immune response.
Claims51
Use of a vector of the type comprising a nonliquid hydrophilic core for the preparation of a medication intended for the treatment of cancers and/or viral diseases, said vector being combined in the medication with at least one substance other than an antigen capable of modulating the immune response.
Use according to any one of the preceding claims, characterized in that the substance/vector weight ratio is comprised between circa 1% and 20%, preferably between circa 5% and 10%.
Use according to any one of the preceding claims, characterized in that the substance other than an antigen capable of modulating the immune response is a protein of therapeutic value which plays a role in the functioning of the immune system, an adjuvant or a substance capable of modifying the Th1/Th2 balance, or a mixture of these.
Use of a vector according to any one of the preceding claims, characterized in that the cancer to be treated is of the nonimmunogenic or weakly immunogenic type.
Use of a vector according to any one of the preceding claims, characterized in the medication is intended for administration via the nasal or oral route.
Use of a vector comprising:
- a) a nonliquid hydrophilic core constituted by a naturally or chemically cross-linked matrix of polysaccharides or oligosaccharides on which are grafted ionic ligands of positive or negative charge,
- b) an external layer constituted at least in part by amphiphilic compounds associated in the core by hydrophobic interactions and/or ionic bonds, and
- c) incorporating IL-2
- for the preparation of a medication intended for the administration of IL-2 in injectable form in the absence of albumin.
Process for improving the immunomodulatory properties of a substance other than an antigen capable of modulating the immune response, characterized in that it comprises mixing of said substance with vectors of the type comprising a nonliquid hydrophilic core.
Pharmaceutical composition, characterized in that it comprises:
- a vector of the type comprising a nonliquid hydrophilic core constituted by a matrix of naturally or chemically cross-linked polysaccharides or oligosaccharides on which are grafted ionic ligands and possibly an external layer constituted at least in part of amphiphilic compounds associated with the core by hydrophobic interactions and/or ionic bonds, and
- at least one protein of therapeutic value, and/or an adjuvant and/or a substance capable of modifying the Th1/Th2 balance.
Use of a vector of the type comprising a nonliquid hydrophilic core for the preparation of a vaccine composition, said vector being mixed in the composition with at least one antigen and at least one substance capable of modulating the immunologic response to said antigen.
Vaccine composition, characterized in that it comprises:
- an antigen or a mixture of antigens,
- a vector of the type comprising a nonliquid hydrophilic core constituted by a matrix of naturally or chemically cross-linked polysaccharides or oligosaccharides on which are grafted ionic ligands and possibly an external layer constituted at least in part of amphiphilic compounds associated with the core by hydrophobic interactions and/or ionic bonds, and
- at least one substance capable of modulating the immunologic response to said antigen.
Dependencies are inferred from the claim text.